Sea Bridge Capital Management

Oppenheimer & Company is a full-service broker-dealer and investment advisory firm that provides financial services to investors, individuals, businesses and institutions. Founded in 1986, the company provides assistance with accumulation, protection, preservation and transfer of wealth. It operates Oppenheimer Asset Management that deals in hedge and mutual funds and domestic investments. Oppenheimer Asset Management s equity portfolio management focuses on large-cap value and small-cap growth investment styles. Oppenheimer & Company s trust company provides trustee, estate settlement, cash management, escrow and custody services to individuals, nonprofit organizations and businesses. The company is a wholly owned subsidiary of Oppenheimer Holdings, which is a financial services holding company. The parent company s other subsidiaries include Oppenheimer Life Agencies and Oppenheimer Trust Company. Oppenheimer & Company has a presence in Florham Park, N.J.

Diversified Investment Strategies, located in Livingston, NJ, is a financial advisory firm specializing in financial planning, tax preparation, estate planning, asset management, and business management services for both individual and commercial clients. With a focus on providing comprehensive financial solutions, Diversified Investment Strategies offers consultation appointments to assist clients in achieving their financial goals. Generated from their available business information

Simphotek Inc, based in Newark, NJ, specializes in advanced medical devices for treatment planning in photodynamic therapy (PDT), particularly for advanced cancers. Their flagship product, Dosie, is an integrated computational device that offers precise simulations of light distribution and drug toxicity, enabling oncologists and medical physicists to tailor treatment plans to individual patients. Dosie employs sophisticated mathematical methods, including Monte Carlo and Finite Element techniques, to model various PDT doses and optimize treatment parameters. By incorporating all relevant variables, Simphotek's technology stands out as the first commercially available solution capable of accurately predicting PDT outcomes across different cancer types. Generated from the website